Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 35: 1024-1026, 1989;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Haeften, T. W.
Right arrow Articles by Konings, C. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Haeften, T. W.
Right arrow Articles by Konings, C. H.

Clinical Chemistry, Vol 35, 1024-1026, Copyright © 1989 by American Association for Clinical Chemistry

Arginine pharmacokinetics in humans assessed with an enzymatic assay adapted to a centrifugal analyzer

TW van Haeften and CH Konings
Department of Endocrinology, Free University Hospital, Amsterdam, The Netherlands.

Arginine is used in supra-physiological concentrations as an insulin secretagogue, in both in vitro and in vivo studies. To investigate the pharmacokinetics of arginine in humans, we have developed a rapid, automated assay of arginine in serum, based on our manual enzymatic method (Clin Chim Acta 1988, 176; 185-94). The limit of linearity of the automated assay was an arginine concentration of 3 mmol/L. Within- run CVs for Ortho control sera with added arginine were 5.5%, 0.8%, and 0.7% at concentrations of 0.16, 1.30, and 2.50 mmol/L, respectively. After 30 min of primed continuous infusions with arginine at infusion rates of 3, 9, 15, and 21 mg/kg per minute, mean (+/- SEM) arginine concentrations in serum from eight volunteers were 1.17 +/- 0.08, 3.44 +/- 0.21, 6.84 +/- 0.58, and 9.25 +/- 0.39 mmol/L, respectively, well within the range of arginine concentrations shown (in vitro) to stimulate insulin secretion. Metabolic clearance of arginine was approximately 11 mL/kg body wt per minute. For the lowest three infusion rates, the half-life (t1/2) of arginine was approximately 15 min and the volume of distribution (Vd) was approximately 290 mL/kg. At the highest infusion rate, t1/2 was significantly increased (27.3 +/- 3.1 min), owing to an increased Vd (446 +/- 83 mL/kg).


The following articles in journals at HighWire Press have cited this article:


Home page
 J. Physiol.Home page
E. N. Dedkova and L. A. Blatter
Characteristics and function of cardiac mitochondrial nitric oxide synthase
J. Physiol., February 15, 2009; 587(4): 851 - 872.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. W. Yeo, I. Rooslamiati, R. Gitawati, E. Tjitra, D. A. Lampah, E. Kenangalem, Y. R. McNeil, R. N. Price, N. M. Anstey, and S. B. Duffull
Pharmacokinetics of L-Arginine in Adults with Moderately Severe Malaria
Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4381 - 4387.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
R. D. Peluffo
L-Arginine currents in rat cardiac ventricular myocytes
J. Physiol., May 1, 2007; 580(3): 925 - 936.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
P. Forte, B. J. Kneale, E. Milne, P. J. Chowienczyk, A. Johnston, N. Benjamin, and J. M. Ritter
Evidence for a Difference in Nitric Oxide Biosynthesis Between Healthy Women and Men
Hypertension, October 1, 1998; 32(4): 730 - 734.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American Association for Clinical Chemistry.